

# CLL Global Research Foundation Grant Application Guidelines

## I. About CLL Global Research Foundation

CLL Global Research Foundation (CLL Global) is a non-profit organization dedicated to accelerating the development of treatments and potential cures for chronic lymphocytic leukemia (CLL) and related leukemias and lymphomas. Our mission is to advance innovative research that has the potential to impact clinical care within two to three years.

CLL Global focuses on fast-tracking funding to support the development of diagnostic, monitoring, and therapeutic tools. Patients and families play a central role in guiding our mission, contributing both funding and strategic insight. CLL Global is a public charity, exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code.

---

## II. Funding Overview

Grants are awarded for specific research projects rather than general laboratory support. Each award covers an initial one-year period and must include a complete, detailed budget justification.

Key funding terms:

- A maximum of 5% of awarded funds may be allocated to institutional overhead.
  - Awards must be activated within three months of notification.
- 

## III. Eligibility

Eligible applicants must:

- Hold an M.D., Ph.D., or equivalent degree.
- Be affiliated with an accredited academic or research institution (domestic or international).
- Demonstrate expertise in CLL research and access to an adequate research environment.

Each applicant may submit only one proposal as principal investigator per funding cycle. Collaborations across institutions are allowed.

---

## IV. Review Criteria

All invited applicants are expected to meet baseline qualifications:

- Commitment to CLL research.
- Strong investigator credentials (education, publications, track record).
- Sufficient research infrastructure (lab space, patient population, support systems).

Applications will be evaluated on:

- Alignment with CLL Global's mission and research priorities.
  - Innovation and originality.
  - Scientific rationale and potential clinical relevance.
  - Feasibility within the proposed timeline and budget.
  - Potential to accelerate development of treatments, diagnostics, or monitoring tools.
  - Strategic use of CLL Global funding to enable or enhance the proposed work.
- 

## V. Review Process

All applications undergo a **peer-review process** by independent reviewers and the **CLL Global Scientific Advisory Board**. Recommendations will be submitted to the **Board of Directors**, which will determine funding allocations per working group.

All review outcomes and deliberations are confidential. The Board reserves the right to adjust the number of awards and total funding amounts at any time.

---

## VI. Award Terms

### A. Use of Funds

Funds must be used solely for the project outlined in the application. Reallocation among budget categories is permitted unless it exceeds the following restrictions:

- **Institutional overhead** is capped at 5%.
- **Travel costs** are limited to \$3,000 per site (for research or data presentation purposes).

- **Equipment purchases** are capped at \$20,000 unless pre-approved.

CLL Global reserves the right to cancel awards if the contract is not executed within three months of notification. Payments are made quarterly to the institution, which is responsible for appropriate fund disbursement.

Violations of terms may result in suspension or termination of funding. Any unspent funds must be returned if a grant is terminated. Changes in institutional affiliation must be reported with an impact statement; fund transfers will be reviewed on a case-by-case basis.

Grant awards do not imply an employment relationship. CLL Global assumes no legal responsibility for project execution.

---

## B. Ongoing Reporting and Engagement

Grantees are required to:

- Submit a **scientific progress report** at 12 months, including publications and a lay summary for donors. A final payment (12.5% of the award) is contingent on report submission.
- Provide a **financial report** within 90 days of grant expiration. Unused funds may be requested for return.

Grantees must acknowledge CLL Global support in all resulting publications and presentations. Copies of research outputs should be shared with CLL Global during and for two years after the grant period.

Awardees agree to:

- Engage in discussions about their research's impact on CLL treatment and cure.
- Participate in outreach activities with the Board and donor community as requested.
- Inform CLL Global of any **patent applications** arising from funded work. Royalty-sharing terms will be addressed in the research agreement if a product is developed.

## C. Regulatory Compliance

Before grant activation, awardees must provide:

- **IRB approval** (or exemption certificate) for any research involving human subjects.
- **IACUC approval** for projects involving animals.
- A statement outlining **biohazard risks and safety measures**.

It is the investigator's responsibility to obtain timely approvals. CLL Global assumes no liability for biohazards and must be held harmless for any resulting issues.